JAN H WESTERMAN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
- Where
- JASPER, AL
- NPI
- 1285674150
- Received
- $19,801 in 100 records, 2019 to 2025 ($2,619 general, $17,181 research)
- As principal investigator
- $831,154 of research payments to others in 117 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 12 | $1,247 |
| 2024 | General payment | 3 | $58 |
| 2023 | General payment | 10 | $204 |
| 2022 | General payment | 2 | $53 |
| 2022 | Research payment | 5 | $9,552 |
| 2021 | General payment | 9 | $150 |
| 2021 | Research payment | 1 | $7,629 |
| 2020 | General payment | 9 | $134 |
| 2019 | General payment | 49 | $770 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| First Wave BioPharma, Inc. | 5 | $9,552 | 2022 |
| Eli Lilly and Company | 1 | $7,629 | 2021 |
| Olympus Corporation of the Americas | 7 | $1,147 | 2025 |
| GlaxoSmithKline, LLC. | 21 | $256 | 2019–2025 |
| AstraZeneca Pharmaceuticals LP | 13 | $226 | 2019–2023 |
| Philips North America LLC | 11 | $212 | 2019–2020 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $128 | 2019–2024 |
| Axsome Therapeutics, Inc. | 6 | $107 | 2023–2024 |
| HARMONY BIOSCIENCES LLC | 5 | $105 | 2020–2023 |
| Grifols USA, LLC | 5 | $98 | 2019–2025 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 | 2019–2022 |
| Circassia Inc. | 2 | $38 | 2019 |
| Insmed, Inc. | 2 | $38 | 2019 |
| JAZZ PHARMACEUTICALS INC. | 2 | $37 | 2019 |
| Mallinckrodt Enterprises LLC | 2 | $31 | 2019 |
| Genentech USA, Inc. | 2 | $29 | 2019 |
| Inspire Medical Systems, Inc. | 1 | $23 | 2025 |
| Shire North American Group Inc | 1 | $19 | 2019 |
| Amgen Inc. | 1 | $19 | 2025 |
| Horizon Therapeutics plc | 1 | $18 | 2021 |
| Vapotherm Inc | 1 | $14 | 2025 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 6 | $17,181 |
| Food and Beverage | 89 | $1,500 |
| Travel and Lodging | 5 | $1,118 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-10-21 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-06 | Grifols USA, LLC | $21 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-07-12 | Olympus Corporation of the Americas | $199 | Travel and Lodging | In-kind items and services | Spiration Valve System Device, Endotherapy | 2025 | |
| 2025-07-12 | Olympus Corporation of the Americas | $24 | Food and Beverage | In-kind items and services | Spiration Valve System Device, Endotherapy | 2025 | |
| 2025-07-11 | Olympus Corporation of the Americas | $29 | Travel and Lodging | In-kind items and services | Spiration Valve System Device, Endotherapy | 2025 | |
| 2025-07-11 | Olympus Corporation of the Americas | $25 | Travel and Lodging | In-kind items and services | Spiration Valve System Device, Endotherapy | 2025 | |
| 2025-07-10 | Olympus Corporation of the Americas | $4 | Food and Beverage | In-kind items and services | Device | 2025 | |
| 2025-07-09 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-06-13 | Olympus Corporation of the Americas | $829 | Travel and Lodging | In-kind items and services | Spiration Valve System Device, Endotherapy | 2025 | |
| 2025-06-13 | Olympus Corporation of the Americas | $35 | Travel and Lodging | In-kind items and services | Spiration Valve System Device, Endotherapy | 2025 | |
| 2025-03-27 | Vapotherm Inc | $14 | Food and Beverage | In-kind items and services | VAPOTHERM Device, RESPIRATORY | 2025 | |
| 2025-01-14 | Inspire Medical Systems, Inc. | $23 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2024-10-15 | Axsome Therapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2024 | |
| 2024-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2024 | |
| 2024-02-05 | Axsome Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2024 | |
| 2023-12-18 | Axsome Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2023 | |
| 2023-11-27 | Axsome Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2023 | |
| 2023-11-16 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-15 | Axsome Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2023 | |
| 2023-08-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2023 | |
| 2023-05-03 | Grifols USA, LLC | $21 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2023 | |
| 2023-04-25 | Axsome Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2023 | |
| 2023-04-18 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-03-16 | HARMONY BIOSCIENCES LLC | $29 | Food and Beverage | Cash or cash equivalent | WAKIX Drug, SLEEP MEDICINE | 2023 | |
| 2023-01-31 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2022-11-14 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2022 | |
| 2022-09-28 | First Wave BioPharma, Inc. | $4,500 | Research payment | Cash or cash equivalent | Niclosamide | 2022 | |
| 2022-09-28 | First Wave BioPharma, Inc. | $2,350 | Research payment | Cash or cash equivalent | Niclosamide | 2022 | |
| 2022-09-28 | First Wave BioPharma, Inc. | $1,352 | Research payment | Cash or cash equivalent | Niclosamide | 2022 | |
| 2022-09-28 | First Wave BioPharma, Inc. | $750 | Research payment | Cash or cash equivalent | Niclosamide | 2022 | |
| 2022-09-28 | First Wave BioPharma, Inc. | $600 | Research payment | Cash or cash equivalent | Niclosamide | 2022 | |
| 2022-04-27 | Regeneron Healthcare Solutions, Inc. | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2022 | |
| 2021-11-04 | Horizon Therapeutics plc | $18 | Food and Beverage | In-kind items and services | RAYOS Drug, RAYOS | 2021 | |
| 2021-10-13 | AstraZeneca Pharmaceuticals LP | $11 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-09-28 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2021 | |
| 2021-09-14 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-08-10 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2021 | |
| 2021-06-22 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-06-08 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-05-11 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2021 | |
| 2021-01-26 | Eli Lilly and Company | $7,629 | Research payment | In-kind items and services | ADAPTIVE PLATFORM TREATMENT TRIAL FOR OUTPATIENTS WITH COVID-19 | 2021 | |
| 2021-01-20 | HARMONY BIOSCIENCES LLC | $23 | Food and Beverage | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2021 | |
| 2020-12-15 | Philips North America LLC | $11 | Food and Beverage | Cash or cash equivalent | (8874) inCourage Device, Dental and Oral Health | 2020 | |
| 2020-11-11 | HARMONY BIOSCIENCES LLC | $13 | Food and Beverage | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2020 | |
| 2020-10-13 | HARMONY BIOSCIENCES LLC | $26 | Food and Beverage | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2020 | |
| 2020-09-29 | Philips North America LLC | $14 | Food and Beverage | Cash or cash equivalent | (8874) inCourage Device, Dental and Oral Health | 2020 | |
| 2020-09-14 | HARMONY BIOSCIENCES LLC | $12 | Food and Beverage | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2020 | |
| 2020-09-09 | Philips North America LLC | $12 | Food and Beverage | Cash or cash equivalent | (8874) inCourage Device, Dental and Oral Health | 2020 | |
| 2020-04-14 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-04-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | STIOLTO Drug, RESPIRATORY | 2020 | |
| 2020-03-04 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | ANORO ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2019-12-11 | Grifols USA, LLC | $16 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2019 | |
| 2019-12-04 | Philips North America LLC | $18 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-11-11 | Philips North America LLC | $18 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-10-30 | JAZZ PHARMACEUTICALS INC. | $20 | Food and Beverage | In-kind items and services | XYREM Drug, NEUROLOGY | 2019 | |
| 2019-10-28 | Insmed, Inc. | $19 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2019 | |
| 2019-10-23 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | BEVESPI AEROSPHERE Drug, Respiratory | 2019 | |
| 2019-10-16 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-10-14 | Philips North America LLC | $16 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-10-03 | GlaxoSmithKline, LLC. | $4 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-10-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-09-30 | GlaxoSmithKline, LLC. | $5 | Food and Beverage | In-kind items and services | BREO Drug, RESPIRATORY | 2019 | |
| 2019-09-25 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | BEVESPI AEROSPHERE Drug, Respiratory | 2019 | |
| 2019-09-19 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | BREO Drug, RESPIRATORY | 2019 | |
| 2019-08-29 | Genentech USA, Inc. | $15 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2019 | |
| 2019-08-27 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | BEVESPI AEROSPHERE Drug, Respiratory | 2019 | |
| 2019-08-14 | JAZZ PHARMACEUTICALS INC. | $17 | Food and Beverage | In-kind items and services | XYREM Drug, NEUROLOGY | 2019 | |
| 2019-07-15 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | BEVESPI AEROSPHERE Drug, Respiratory | 2019 | |
| 2019-07-15 | Philips North America LLC | $20 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-07-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-06-27 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-06-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-06-20 | Philips North America LLC | $24 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-05-22 | Philips North America LLC | $24 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-05-21 | Genentech USA, Inc. | $14 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2019 | |
| 2019-05-16 | Mallinckrodt Enterprises LLC | $11 | Food and Beverage | In-kind items and services | ACTHAR Biological, AUTOIMMUNE AND RARE DISEASE | 2019 | |
| 2019-05-16 | AstraZeneca Pharmaceuticals LP | $11 | Food and Beverage | In-kind items and services | BEVESPI AEROSPHERE Drug, Respiratory | 2019 | |
| 2019-05-01 | GlaxoSmithKline, LLC. | $2 | Food and Beverage | In-kind items and services | BREO Drug, RESPIRATORY | 2019 | |
| 2019-04-30 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-04-21 | Philips North America LLC | $26 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-04-18 | Circassia Inc. | $19 | Food and Beverage | In-kind items and services | TUDORZA PRESSAIR Drug, PULMONARYRESPIRATORY DISEASES | 2019 | |
| 2019-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-04-09 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | BREO Drug, RESPIRATORY | 2019 | |
| 2019-04-04 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2019 | |
| 2019-04-01 | Insmed, Inc. | $18 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2019 | |
| 2019-03-10 | Philips North America LLC | $25 | Food and Beverage | Cash or cash equivalent | Trilogy 100 Device, Pulmonary/Respiratory Diseases | 2019 | |
| 2019-03-07 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-03-06 | Grifols USA, LLC | $19 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2019 | |
| 2019-02-28 | Circassia Inc. | $18 | Food and Beverage | In-kind items and services | TUDORZA PRESSAIR Drug, PULMONARYRESPIRATORY DISEASES | 2019 | |
| 2019-02-28 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | BREO Drug, RESPIRATORY | 2019 | |
| 2019-02-26 | Mallinckrodt Enterprises LLC | $19 | Food and Beverage | In-kind items and services | ACTHAR Biological, AUTOIMMUNE AND RARE DISEASE | 2019 | |
| 2019-02-22 | Shire North American Group Inc | $19 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2019 | |
| 2019-02-20 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-02-07 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-02-06 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-02-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-01-23 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | BEVESPI AEROSPHERE Drug, Respiratory | 2019 | |
| 2019-01-22 | Grifols USA, LLC | $18 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2019 | |
| 2019-01-16 | Sunovion Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 | |
| 2019-01-03 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | BREO Drug, RESPIRATORY | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-24 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $8,880 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-07-09 | GlaxoSmithKline, LLC. | JASPER SUMMIT RESEARCH LLC | $3,080 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | 2025 |
| 2025-02-19 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $465 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-02-07 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $1,621 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-01-21 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $1,735 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2025 |
| 2025-01-08 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $1,690 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2024-12-11 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $1,690 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-11-19 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $2,609 | Ph IIb of Astegolimab in COPD | 2024 |
| 2024-10-25 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $7,550 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-10-25 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $5,846 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-10-01 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $8,450 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-08-26 | Mylan Specialty L.P. | Jasper Summit Research, LLC | $3,000 | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adult | 2024 |
| 2024-08-21 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $11,234 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-08-21 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $13,686 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-06-12 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $11,913 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-05-03 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $2,535 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-04-05 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $28,785 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-02-02 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $2,535 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-01-24 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $9,000 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-01-24 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $1,500 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-01-24 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $2,513 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-01-23 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $1,772 | Ph IIb of Astegolimab in COPD | 2024 |
| 2024-01-10 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $16,557 | Ph III OLE of Astegolimab in COPD | 2024 |
| 2024-01-04 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $656 | Ph IIb of Astegolimab in COPD | 2024 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $1,636 | AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD whic | 2023 |
| 2023-12-27 | United Therapeutics Corporation | JASPER SUMMIT RESEARCH LLC | $5,944 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-14 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $33,401 | Ph IIb of Astegolimab in COPD | 2023 |
| 2023-12-13 | Chiesi USA, Inc. | JASPER SUMMIT RESEARCH LLC | $2,500 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2023 |
| 2023-11-01 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $6,803 | Ph III OLE of Astegolimab in COPD | 2023 |
| 2023-10-18 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $6,201 | Ph III OLE of Astegolimab in COPD | 2023 |
| 2023-08-28 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $2,640 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2023 |
| 2023-07-24 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $852 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2023 |
| 2023-06-20 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $22,187 | Ph IIb of Astegolimab in COPD | 2023 |
| 2023-05-25 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $2,420 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2023 |
| 2023-05-11 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $14,619 | Ph IIb of Astegolimab in COPD | 2023 |
| 2023-04-25 | Chiesi USA, Inc. | JASPER SUMMIT RESEARCH LLC | $1,200 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2023 |
| 2023-04-18 | United Therapeutics Corporation | JASPER SUMMIT RESEARCH LLC | $518 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-04-17 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $1,705 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2023 |
| 2023-03-21 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $3,599 | Ph IIb of Astegolimab in COPD | 2023 |
| 2023-03-21 | United Therapeutics Corporation | JASPER SUMMIT RESEARCH LLC | $259 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-03-13 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $1,510 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2023 |
| 2023-03-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Jasper Summit Research Lab | $10,500 | CatC inhibitor Phase II in bronchiectasis | 2023 |
| 2023-03-02 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $5,064 | Ph IIb of Astegolimab in COPD | 2023 |
| 2023-03-01 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $8,260 | Ph IIb of Astegolimab in COPD | 2023 |
| 2023-02-22 | United Therapeutics Corporation | JASPER SUMMIT RESEARCH LLC | $1,036 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-02-21 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $1,342 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2023 |
| 2023-02-16 | Chiesi USA, Inc. | JASPER SUMMIT RESEARCH LLC | $10,000 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2023 |
| 2023-02-06 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $3,500 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2023 |
| 2023-01-27 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $3,315 | AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD whic | 2023 |
| 2023-01-24 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $21,323 | Ph IIb of Astegolimab in COPD | 2023 |
| 2023-01-23 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $2,745 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2023 |
| 2023-01-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Jasper Summit Research Lab | $3,904 | CatC inhibitor Phase II in bronchiectasis | 2023 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $6,820 | AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD whic | 2022 |
| 2022-12-19 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $1,342 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-12-06 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $7,641 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-11-28 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $4,500 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2022 |
| 2022-11-15 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $1,500 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-11-15 | Genentech, Inc. | JASPER SUMMIT RESEARCH LLC | $1,500 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-11-02 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $9,875 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-10-25 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $13,501 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-10-18 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $300 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-09-26 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $300 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-09-26 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $300 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-09-01 | GlaxoSmithKline, LLC. | JASPER SUMMIT RESEARCH LLC | $3,500 | A PHASE I/II, OBSERVER-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO | 2022 |
| 2022-09-01 | GlaxoSmithKline, LLC. | JASPER SUMMIT RESEARCH LLC | $1,250 | A PHASE I/II, OBSERVER-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO | 2022 |
| 2022-08-24 | United Therapeutics Corporation | JASPER SUMMIT RESEARCH LLC | $12,412 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2022 |
| 2022-08-23 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $16,440 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-08-15 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $900 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-08-15 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $310 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-08-02 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $2,515 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-08-01 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $17,100 | A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy | 2022 |
| 2022-07-26 | Mylan Specialty L.P. | Jasper Summit Research, LLC | $5,000 | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adult | 2022 |
| 2022-07-13 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $13,815 | AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD whic | 2022 |
| 2022-06-28 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $11,941 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-06-28 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $3,822 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-06-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Jasper Summit Research, LLC | $92 | CatC inhibitor Phase II in bronchiectasis | 2022 |
| 2022-06-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Jasper Summit Research Lab | $14,757 | CatC inhibitor Phase II in bronchiectasis | 2022 |
| 2022-06-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Jasper Summit Research, LLC | $14,533 | CatC inhibitor Phase II in bronchiectasis | 2022 |
| 2022-05-23 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $7,250 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-05-10 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $11,601 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-03-22 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $4,248 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-02-25 | GlaxoSmithKline, LLC. | JASPER SUMMIT RESEARCH LLC | $1,778 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | 2022 |
| 2022-02-15 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $1,914 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-02-03 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $1,731 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-02-01 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $7,500 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-02-01 | Hoffmann-La Roche Limited | JASPER SUMMIT RESEARCH LLC | $3,658 | PH IIB OF ASTEGOLIMAB IN COPD | 2022 |
| 2022-01-18 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $10,443 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, an | 2022 |
| 2022-01-05 | Novartis Pharmaceuticals Corporation | BIOPHARMA INFORMATIC LLC | $60,784 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ENSOVIBEP (MP0420) IN AMBULATORY ADULT PATIENTS WIT | 2022 |
| 2022-01-04 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $11,500 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and | 2022 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $1,982 | AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD whic | 2021 |
| 2021-12-13 | SANOFI US SERVICES INC. | JASPER SUMMIT RESEARCH LLC | $11,500 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2021 |
| 2021-08-27 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $4,016 | AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD whic | 2021 |
| 2021-04-03 | GlaxoSmithKline, LLC. | JASPER SUMMIT RESEARCH LLC | $443 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | 2021 |
| 2021-02-13 | GlaxoSmithKline, LLC. | JASPER SUMMIT RESEARCH LLC | $17,221 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | 2021 |
| 2021-01-26 | GlaxoSmithKline, LLC. | JASPER SUMMIT RESEARCH LLC | $850 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | 2021 |
| 2021-01-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | JASPER SUMMIT RESEARCH LLC | $20,588 | Tio & Olo versus PBO stratified by PIFR | 2021 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $464 | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | JASPER SUMMIT RESEARCH LLC | $1,469 | A Phase IIIB 6 Month Doubleblind Double dummy Randomized Parallel group Multicenter Exacerbation Study of Symbicort pMD | 2020 |
| 2020-12-24 | GlaxoSmithKline, LLC. | JASPER SUMMIT RESEARCH-JASPER-UNITED STA | $3,850 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | 2020 |
| 2020-06-09 | Mylan Specialty L.P. | JASPER SUMMIT RESEARCH LLC | $1,500 | PIFR 2 | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jasper, AL, county Walker County, AL, state Alabama; placed by its city name.
| Measure | Place (city or town) Jasper, AL | County Walker County, AL | State Alabama |
|---|---|---|---|
| Population B01003 | 14,442 | 64,841 | 5,086,768 |
| Population, 2020 census P1 | 14,572 | 65,342 | 5,024,279 |
| Median age B01002 | 35.7 | 40.6 | 39.3 |
| Under 18 B01001 | 25.7% | 22.9% | 22.2% |
| 65 and over B01001 | 20.8% | 19.7% | 17.8% |
| Households B11001 | 5,265 | 25,388 | 1,997,247 |
| Foreign born B05002 | 2.1% | 1.5% | 4.0% |
| Median household income B19013 | $66,238 | $56,509 | $63,999 |
| Median family income B19113 | $81,406 | $72,343 | $83,032 |
| Per capita income B19301 | $33,377 | $29,460 | $36,087 |
| Poverty rate B17001 | 15.9% | 18.5% | 15.6% |
| Unemployment rate B23025 | 3.5% | 4.9% | 4.7% |
| Civilian labor force B23025 | 6,333 | 27,474 | 2,367,787 |
| Mean commute (minutes) B08013 | 26.8 | 31.2 | 25.5 |
| Bachelor's degree or higher B15003 | 28.2% | 16.6% | 28.4% |
| Housing units B25001 | 6,162 | 30,366 | 2,337,265 |
| Owner-occupied B25003 | 66.4% | 76.1% | 70.2% |
| Renters B25003 | 33.6% | 23.9% | 29.8% |
| Median home value B25077 | $215,700 | $135,900 | $209,900 |
| Median gross rent B25064 | $721 | $756 | $1,007 |
| White, not Hispanic B03002 | 78.5% | 86.2% | 63.4% |
| Black B03002 | 13.2% | 6.3% | 25.6% |
| Hispanic or Latino B03002 | 3.9% | 3.8% | 5.6% |
| Asian B03002 | 0.7% | 0.4% | 1.4% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.3% |
Economy now FRED unemployment 3.5% in Sep 2026 (2.8% a year earlier); per capita personal income $59,754 in 2025, up 30% in five years (+4.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jasper, AL.
Comments